CPAP Effect on Lipid Profile and Hyperuricemia in Patients With Dyslipidemia and Moderate-severe Obstructive Sleep Apnea

Launched by HOSPITAL UNIVERSITARIO LA PAZ · Jun 14, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a treatment called CPAP (Continuous Positive Airway Pressure) on patients who have both moderate to severe obstructive sleep apnea and dyslipidemia, which is an imbalance of fats in the blood. The main goal is to see if using CPAP for 12 months, along with regular health advice about diet and exercise, can improve cholesterol levels and lower uric acid in these patients. The study will also look at how this treatment affects other health factors like blood sugar, cardiovascular risk, and overall quality of life.

To participate in the trial, individuals need to be between 35 and 80 years old and have a diagnosis of dyslipidemia and moderate to severe sleep apnea. They should not already be using CPAP or have severe daytime sleepiness or high blood pressure that requires treatment. Participants will be randomly assigned to either receive standard health guidance or the same guidance along with CPAP treatment. Throughout the study, researchers will monitor various health markers and any side effects. This trial is currently recruiting participants, and those who join will contribute valuable information about the potential benefits of CPAP therapy in managing their conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subjects from 35 to 80 years old
• • Diagnosis of dyslipidemia. It will be considered as such, the existence of a previous clinical record of a diagnosis of dyslipidemia associated with treatment with lipidlowering agents, treatment with lipid-lowering agents or the presence of an altered blood test in the last two months, using the following cut-off points: total cholesterol ≥ 200 mg/dl, triglycerides ≥ 180 mg/dl, HDL-cholesterol ≤ 40 mg/dl or LDL-cholesterol ≥ 150 mg/dl.
• • Moderate-severe sleep apnea, defined by AHI \> 15 h-1 .
• Exclusion Criteria:
• • Predominance of central apneas-hypopneas, defined as more than 25% of total respiratory events.
• • Patients with indications for CPAP treatment according to the International Sleep Consensus: hypertensive, excessive daytime sleepiness (Epworth Sleepiness Scale \> 11) or impaired sleep-related quality of life considered relevant by their regular physician.
• • Professional drivers, at-risk profession or respiratory insufficiency (according to criteria of the clinical pathway for the diagnosis and treatment of sleep-disordered breathing).
• • Pretreatment with CPAP